title: Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma.
abstract: The purpose of this study was to assess the feasibility and efficacy of stereotactic ablative radiotherapy (SABR) for liver tumor in patients with Barcelona Clinic Liver Cancer (BCLC)-C stage hepatocellular carcinoma (HCC). We retrospectively reviewed the medical records of 35 patients between 2003 and 2011. Vascular invasion was diagnosed in 32 patients, extrahepatic metastases in 11 and both in 8. Thirty-two patients were categorized under Child-Pugh (CP) class A and 3 patients with CP class B. The median SABR dose was 45 Gy (range, 30-60 Gy) in 3-5 fractions. The median survival time was 14 months. The 1- and 3-yr overall survival (OS) rate was 52% and 21%, respectively. On univariate analysis, CP class A and biologically equivalent dose ≥ 80 Gy(10) were significant determinants of better OS. Severe toxicity above grade 3, requiring prompt therapeutic intervention, was observed in 5 patients. In conclusion, SABR for BCLC-C stage HCC showed 1-yr OS rate of 52% but treatment related toxicity was moderate. We suggest that patients with CP class A are the best candidate and at least SABR dose of 80 Gy(10) is required for BCLC-C stage.
authors: Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
authors: Sun Hyun
authors: SH
authors: Bae
authors: Mi-Sook
authors: MS
authors: Kim
authors: Chul Koo
authors: CK
authors: Cho
authors: Kum Bae
authors: KB
authors: Kim
authors: Dong Han
authors: DH
authors: Lee
authors: Chul Ju
authors: CJ
authors: Han
authors: Su Cheol
authors: SC
authors: Park
authors: Young Han
authors: YH
authors: Kim
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000532:radiotherapy*; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017093:Liver Failure / Q000209:etiology; D008113:Liver Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009187:Myelitis / Q000209:etiology; D009367:Neoplasm Staging; D011379:Prognosis; D011829:Radiation Dosage; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013238:Stereotaxic Techniques; D015996:Survival Rate
keywords: Carcinoma; Hepatocellular; Neoplasm Staging; Radiotherapy; Stereotactic Techniques
references: Lancet Oncol. 2009 Jan;10(1):25-34
references: 19095497
references: Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e447-53
references: 21645977
references: BMC Cancer. 2010 Sep 03;10:475
references: 20813065
references: Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i19-27
references: 20870915
references: Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
references: 2032882
references: Korean J Hepatol. 2009 Sep;15(3):391-423
references: 19783891
references: J Gastroenterol. 2005 Mar;40(3):225-35
references: 15830281
references: Cancer. 2012 Nov 1;118(21):5424-31
references: 22570179
references: J Cancer Res Clin Oncol. 2012 Jul;138(7):1121-9
references: 22402598
references: Am J Clin Oncol. 2006 Dec;29(6):568-75
references: 17148993
references: N Engl J Med. 2008 Jul 24;359(4):378-90
references: 18650514
references: Hepatol Int. 2010 Mar 18;4(2):439-74
references: 20827404
references: J Hepatol. 2006 Apr;44(4):723-31
references: 16488051
references: Eur J Cancer. 2008 May;44(7):1000-6
references: 18337087
references: Hepatology. 2005 Apr;41(4):707-16
references: 15795889
references: N Engl J Med. 1995 May 11;332(19):1256-61
references: 7708069
references: J Surg Oncol. 2010 Sep 1;102(3):209-14
references: 20740576
references: Oncologist. 2010;15 Suppl 4:23-33
references: 21115578
references: Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e469-74
references: 23078899
references: J Hepatol. 2004 Jan;40(1):124-31
references: 14672623
references: Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2004-11
references: 21621346
references: Lancet Oncol. 2011 Jul;12(7):654-62
references: 21684210
references: BMC Cancer. 2008 Nov 27;8:351
references: 19038025
references: Oncology. 2011;81 Suppl 1:158-64
references: 22212951
references: Hepatol Res. 2011 Sep;41(9):813-24
references: 21696524